Departments, Centers, & Programs:
Mass Eye and Ear Longwood
800 Huntington Avenue
Boston, MA 02215
- M.D.; Ph.D., Stanford University School of Medicine
- Residency, Duke University Medical Center
- Fellowship, Duke University Medical Center
American Board Certifications
- Ophthalmology, American Board of Ophthalmology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Margeta specializes in glaucoma, which is a chronic blinding disease characterized by gradual loss of retinal ganglion cells and cupping of the optic nerve. Elevated intraocular pressure remains the only modifiable risk factor for glaucoma; currently there no treatments conferring retinal ganglion cell neuroprotection or reversing existing visual field loss. As a Harvard-Vision Clinical Scientist Development Program (K12) scholar, Dr. Margeta is investigating the role of retinal neuroinflammation in the pathogenesis of glaucoma, with the goal of developing novel neuroprotective treatments for this progressive blinding disease.
1. Pan BX, Margeta MA. Elevated Intraocular Pressure in a Young Man With a History of Laser-Assisted In Situ Keratomileusis. JAMA Ophthalmol. 2019 03 01; 137(3):318-319.
2. Liu WW, Margeta MA. Imaging Retinal Ganglion Cell Death and Dysfunction in Glaucoma. Int Ophthalmol Clin. 2019; 59(4):41-54.
3. Margeta MA, Lad EM, Proia AD. CD163+ macrophages infiltrate axon bundles of postmortem optic nerves with glaucoma. Graefes Arch Clin Exp Ophthalmol. 2018 Dec; 256(12):2449-2456.
4. Margeta MA, Kuo AN, Proia AD, Freedman SF. Staying away from the optic nerve: a formula for modifying glaucoma drainage device surgery in pediatric and other small eyes. J AAPOS. 2017 02; 21(1):39-43.e1.
5. Margeta MA, Buckley EG, El-Dairi MA. Low cerebrospinal fluid protein in prepubertal children with idiopathic intracranial hypertension. J AAPOS. 2015 Apr; 19(2):135-9.